AstraZeneca and Daiichi Sankyo’s Enhertu Eyes 50% Of Breast Cancer Market Following HER2-Low Data

 
• By Ayisha Sharma

Transformative product is the first to demonstrate benefit in HER2-low metastatic breast cancer, broadening its market potential to nearly half of all breast cancers.

Close up of breast cancer.
Enhertu Was Previously Looking At 20% Of The Market. • Source: Alamy

More from Clinical Trials

More from R&D